Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session

Published 12/09/2022, 17:45
Updated 12/09/2022, 18:40
© Reuters.  Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session

© Reuters. Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session

Gainers

  • Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
  • NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) gained 69% to $0.4664 after the company announced a 1-for-30 reverse stock split.
  • Arqit Quantum Inc. (NASDAQ: ARQQ) shares climbed 34.7% to $7.53. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference later today.
  • InMed Pharmaceuticals Inc. (NASDAQ: INM) gained 32.5% to $14.60 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
  • Ra Medical Systems, Inc. (NYSE: RMED) surged 28% to $0.1865 after the company announced a merger agreement with Catheter Precision. Catheter Precision will become a wholly owned subsidiary of Ra Medical.
  • Vinco Ventures, Inc. (NASDAQ: BBIG) gained 25% to $1.2500.
  • IHS Holding Limited (NYSE: IHS) jumped 19.2% to $7.47. IHS Holding, last month, said Q2 EPS results down year-over-year.
  • Gogoro Inc. (NASDAQ: GGR) gained 19.1% to $5.16. Gogoro recently launched its battery-swapping system and Smart scooters in the Tel Aviv metropolitan area.
  • Ribbon Communications Inc. (NASDAQ: RBBN) rose 19% to $3.8450.
  • Allego N.V. (NYSE: ALLG) gained 18.3% to $5.23.
  • Regulus Therapeutics Inc. (NASDAQ: RGLS) gained 16.8% to $1.94 after the company announced topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. The study demonstrated that RGLS8429 has a favorable safety and PK profile.
  • IDEAYA Biosciences, Inc. (NASDAQ: IDYA) surged 15.6% to $10.70. IDEAYA Biosciences disclosed interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma.
  • Carvana Co. (NYSE: CVNA) rose 13.7% to $41.64. Piper Sandler upgraded Carvana from Neutral to Overweight and lowered the price target from $98 to $73.
  • POINT Biopharma Global Inc. (NASDAQ: PNT) gained 13.4% to $9.72 after the company published a poster at ESMO Congress 2022 highlighting updated safety and efficacy data from its Phase 3 SPLASH trial of PNT2002 in metastatic castration-resistant prostate cancer.
  • Sigma Lithium Corporation (NASDAQ: SGML) jumped 12.8% to $28.16.
  • Clovis Oncology, Inc. (NASDAQ: CLVS) rose 12.2% to $1.29 after the company said Rubraca (Rucaparib) as first-line maintenance treatment improves progression-free survival in women with advanced ovarian cancer across disease risk subgroups.
  • Auddia Inc. (NASDAQ: AUUD) surged 12% to $1.40.
  • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) gained 10.8% to $42.98 after jumping 26% on Friday.
  • Genenta Science S.p.A. (NASDAQ: GNTA) gained 10.6% to $5.30.
  • NIO Inc. (NYSE: NIO) surged 10.2% to $21.13 following positive analyst coverage from Deutsche Bank (ETR:DBKGn) and BofA.
  • NetScout Systems, Inc. (NASDAQ: NTCT) gained 9.7% to $33.70. The company, last month, posted upbeat quarterly earnings.
  • Reborn Coffee, Inc. (NASDAQ: REBN) rose 9.4% to $2.5924. Dennis R Egidi recently reported a 9.5% stake in Reborn Coffee.
  • Eve Holding, Inc. (NYSE: EVEX) gained 9.2% to $8.42. United recently announced a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
  • Asana, Inc. (NYSE: ASAN) gained 9% to $26.87. Asana’s President, CEO and Director Dustin Moskovitz bought a total of 19,273,127 shares at an average price of $18.16.
  • Quhuo Limited (NASDAQ: QH) shares rose 7.5% to $2.96 after the company on Friday said it has determined not to proceed with its proposed offering and sale of securities.
  • Hyperfine, Inc. (NASDAQ: HYPR) rose 7.3% to $1.3090 after declining 6% on Friday. Hyperfine, last month, reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
  • Bristol-Myers Squibb Company (NYSE: NYSE:BMY) rose 5.6% to $74.11. The FDA approved Bristol Myers Squibb Co's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Atlantic Equities maintained Bristol-Myers Squibb with an Overweight and raised the price target from $83 to $87.
  • Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) rose 4.3% to $1.35. The U.S. Food and Drug Administration has approved the company’s lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.
Losers
  • Akari Therapeutics, Plc (NASDAQ: AKTX) shares dropped 25% to $0.7803 after the company announced a $12.75 million registered direct offering.
  • Tuesday Morning Corporation (NASDAQ: TUEM) fell 22.7% to $0.2175 after the company secured commitment for strategic investment from group led by Retail Ecommerce Ventures, the owner of Pier 1 Imports and top consumer brands.
  • Yoshiharu Global Co. (NASDAQ: YOSH) shares fell 22.5% to $3.2301. The company, on Friday, priced its IPO at $4 per share.
  • DICE Therapeutics, Inc. (NASDAQ: DICE) fell 19.6% to $18.20. Stifel, last week, initiated coverage on the stock with a Buy rating and a $37 price target.
  • CleanTech Acquisition Corp. (NASDAQ: CLAQ) dropped 17.7% to $5.02. CleanTech Acquisition and Nauticus Robotics completed business combination to trade under "KITT" effective September 13.
  • Apexigen, Inc. (NASDAQ: APGN) declined 16.6% to $6.35 as the company announced the presentation of new data from a Phase 2 trial evaluating sotigalimab (sotiga) in combination with neoadjuvant chemoradiation for resectable esophageal and gastroesophageal junction (GEJ) cancers.
  • Leap Therapeutics, Inc. (NASDAQ: LPTX) dropped 15.3% to $1.43.
  • Codere Online Luxembourg, S.A. (NASDAQ: CDRO) fell 15.6% to $2.70. Codere Online recently reported Q2 sales results.
  • MOGU Inc. (NYSE: MOGU) fell 13.6% to $2.2475. Mogu’s board of directors, on Friday, authorized a new share repurchase program of up to $10 million of its shares.
  • Nuwellis, Inc. (NASDAQ: NUWE) fell 12.1% to $0.7469.
  • Entrada Therapeutics, Inc. (NASDAQ: TRDA) dropped 11.4% to $13.21. Entrada Therapeutics, last month, posted a Q2 loss of $0.74 per share.
  • ShiftPixy, Inc. (NASDAQ: PIXY) fell 9.8% to $31.06 after gaining 11% on Friday.
  • Azure Power Global Limited (NYSE: AZRE) dropped 9.3% to $5.32.
  • Great Panther Mining Limited (NYSE: GPL) declined 9.2% to $0.2144.
  • Immatics N.V. (NASDAQ: IMTX) fell 9% to $11.69.
  • Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) dropped 8.7% to $1.7250. Ayala Pharmaceuticals presented interim data from RINGSIDE pivotal Phase 2/3 trial of AL102 show confirmed partial response in desmoid tumors, at ESMO Congress.
  • Burning Rock Biotech Limited (NASDAQ: BNR) declined 7.2% to $3.33.
  • Digital Media Solutions, Inc. (NYSE: DMS) fell 6% to $2.0696. Digital Media Solutions shares climbed 72% on Friday after the company received a non-binding go-private proposal from Prism Data for $2.50 per share in cash.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.